Literature DB >> 35610991

Highlights in Ulcerative Colitis From the 17th Congress of the European Crohn's and Colitis Organisation: Commentary.

David T Rubin1.   

Abstract

Entities:  

Year:  2022        PMID： 35610991      PMCID： PMC9122072     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  12 in total

1.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

2.  The Effects of Maintenance Therapy With Upadacitinib on Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 U-ACHIEVE Maintenance Results.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

3.  Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, Proof-of-Concept Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

4.  Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

5.  The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 2b QUASAR Study Results Through Week 12.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2022-04

6.  Telomere shortening in the colonic mucosa of patients with ulcerative colitis.

Authors:  Y Kinouchi; N Hiwatashi; M Chida; F Nagashima; S Takagi; H Maekawa; T Toyota
Journal:  J Gastroenterol       Date:  1998-06       Impact factor: 7.527

7.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

Authors:  Giancarlo Comi; Ludwig Kappos; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Ning Ding; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

8.  Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

Authors:  Jeffrey A Cohen; Giancarlo Comi; Krzysztof W Selmaj; Amit Bar-Or; Douglas L Arnold; Lawrence Steinman; Hans-Peter Hartung; Xavier Montalban; Eva Kubala Havrdová; Bruce A C Cree; James K Sheffield; Neil Minton; Kartik Raghupathi; Vivian Huang; Ludwig Kappos
Journal:  Lancet Neurol       Date:  2019-09-03       Impact factor: 44.182

9.  Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  William J Sandborn; Brian G Feagan; Geert D'Haens; Douglas C Wolf; Igor Jovanovic; Stephen B Hanauer; Subrata Ghosh; AnnKatrin Petersen; Steven Y Hua; Ji Hwan Lee; Lorna Charles; Denesh Chitkara; Keith Usiskin; Jean-Frederic Colombel; Loren Laine; Silvio Danese
Journal:  N Engl J Med       Date:  2021-09-30       Impact factor: 176.079

10.  Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.

Authors:  William J Sandborn; Laurent Peyrin-Biroulet; Daniel Quirk; Wenjin Wang; Chudy I Nduaka; Arnab Mukherjee; Chinyu Su; Bruce E Sands
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-27       Impact factor: 13.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.